微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 34.54% | 21.88% | 18.49% | 110/160 | 22.89% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 29.15% | 4.41% | 39.37% | 122/160 | 33.26% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 20.92% | -16.89% | -13.82% | 138/160 | 51.37% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 24.27% | -15.16% | -14.36% | 136/160 | 51.38% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 28.34% | -6.55% | 1.51% | 126/160 | 32.75% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 27.92% | -19.06% | 10.93% | 127/160 | 38.61% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 25.17% | -25.3% | -12.03% | 127/160 | 52.91% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 28.61% | -0.78% | -5.67% | 125/160 | 53.57% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 30.33% | 12.94% | -12.07% | 112/160 | 6.69% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 34.49% | 36.82% | 2.37% | 112/160 | 21.79% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 33.69% | 40.46% | 16.85% | 105/160 | 54.47% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 28.83% | -6.19% | 7.38% | 132/160 | 55.07% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 26.85% | -4.52% | 6.52% | 121/160 | 47.01% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 25.21% | 5.76% | 5.09% | 131/160 | 47.45% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 23.99% | -29.34% | -21.96% | 115/160 | 54.21% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 30.74% | 3.83% | 9.3% | 128/160 | -143.08% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 28.12% | -11.62% | 17.98% | 109/160 | 56.57% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 23.84% | -25.95% | -29.78% | 121/160 | 54.32% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 33.95% | -7.06% | 14.68% | 94/160 | 55.5% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 29.6% | -16.53% | -6.96% | 121/160 | -1204.25% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 31.82% | -8.5% | -1.15% | 94/160 | 55.47% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 32.19% | -7.17% | -11.88% | 100/160 | 55.36% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 36.53% | 5.75% | 3% | 83/160 | 51.37% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 35.46% | 63.98% | 1.98% | 104/160 | -205.91% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 34.77% | 78.18% | 0.28% | 83/160 | 54.25% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 34.68% | 132.29% | 0.39% | 85/160 | 53.68% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 34.54% | 173.77% | 59.73% | 80/160 | 54.19% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 21.63% | 86.68% | 10.81% | 118/160 | 52.58% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 19.52% | 73.86% | 30.73% | 94/160 | 49.32% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 14.93% | 15.47% | 18.31% | 101/160 | 48.02% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 12.62% | -13.18% | 8.92% | 86/160 | 46.89% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 11.58% | -4.46% | 3.2% | 112/160 | 48.44% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 11.23% | -15.75% | -13.17% | 80/160 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 12.93% | -6.21% | -11.05% | 88/160 | 46.2% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 14.53% | -4.01% | 19.86% | 78/160 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 12.13% | -22.22% | -8.99% | 103/160 | 46.24% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 13.32% | -8.29% | -3.35% | 76/160 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 13.78% | -10.46% | -8.96% | 81/160 | 45.36% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 15.14% | 15.02% | -2.87% | 72/160 | 43.46% | 舒泰神 | 94.4% | 行业排名> |